Welcome to our dedicated page for Gossamer Bio SEC filings (Ticker: GOSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gossamer Bio, Inc. (GOSS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), and its filings offer detailed insight into this strategy.
Through current reports on Form 8‑K, Gossamer Bio reports material events such as quarterly financial results, stockholder meeting outcomes, and significant transactions. Recent 8‑K filings have described results of operations and financial condition, approval of amendments to its 2019 Incentive Award Plan, and the option agreement and plan of merger that grant Gossamer Bio the right to acquire Respira Therapeutics and its pulmonary hypertension candidate RT234. These documents outline share issuances, potential milestone payments, and other key terms.
Investors can also use this page to locate references to the company’s incentive equity plans, employment inducement awards, and stockholder voting results, which appear in filings related to annual meetings and compensation arrangements. While Forms 10‑K and 10‑Q are not reproduced here, they are accessible through EDGAR and provide comprehensive information on research and development expenses, collaboration revenue, cash resources, and risk factors tied to seralutinib and the broader pipeline.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the main points of lengthy reports, track how new equity issuances affect capital structure, and see how clinical and business milestones are reflected in Gossamer Bio’s regulatory record. Real-time updates ensure that new 8‑K, 10‑Q, 10‑K, and Form 4 insider transaction filings for GOSS are surfaced as they are posted to EDGAR, helping users follow the company’s evolving disclosure history.
Gossamer Bio, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer. This filing allows the company to offer common stock, preferred stock, debt securities, warrants and units in one or more future offerings using prospectus supplements.
Any specific terms, prices and uses of proceeds will be detailed in later supplements. Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for pulmonary hypertension, including PAH and PH-ILD. Its common stock trades on the Nasdaq Global Select Market under the symbol GOSS, with a reported price of $2.64 per share on January 27, 2026.
Gossamer Bio, Inc. received an amended Schedule 13G filing showing that BlackRock, Inc. beneficially owns 15,065,708 shares of its common stock as of 12/31/2025. This position represents 6.5% of Gossamer Bio’s outstanding common shares.
BlackRock reports sole voting power over 14,859,077 shares and sole dispositive power over 15,065,708 shares, with no shared voting or dispositive power. The filing explains that these securities are held by certain BlackRock business units and that various underlying persons have rights to dividends or sale proceeds, but no individual holds more than five percent of the total outstanding shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Gossamer Bio.
Gossamer Bio (GOSS) furnished a Form 8-K announcing it issued a press release reporting financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company noted that the information in this item, including Exhibit 99.1, is being furnished and not filed under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated by reference except as specifically stated. The report was signed by Bryan Giraudo, Chief Financial Officer and Chief Operating Officer.
Gossamer Bio (GOSS) reported Q3 2025 results, showing higher collaboration revenue but wider losses. Revenue was $13.3 million for the quarter, up from $9.5 million a year ago, driven by revenue from contracts with collaborators. For the nine months, revenue was $34.7 million versus $105.3 million last year, when results included $88.8 million of license revenue.
The company posted a Q3 net loss of $48.2 million (basic/diluted loss per share $0.21), compared with a $30.8 million loss a year earlier, as research and development expenses rose to $45.5 million. Year to date, operating cash flow was negative $123.0 million.
As of September 30, 2025, cash and cash equivalents were $8.9 million and marketable securities were $171.3 million. Total assets were $208.8 million against total liabilities of $291.2 million, resulting in a stockholders’ equity (deficit) of $(82.3) million. Long‑term convertible senior notes had a net carrying amount of $198.3 million. The company reports that Chiesi accounted for 100% of revenue during the nine‑month period under the collaboration agreement.
Robert Paul Smith Jr., identified as an Officer (Chief Commercial Officer) of Gossamer Bio, Inc. (GOSS), reported a securities acquisition on 10/01/2025. The filing shows an award of 162,500 performance stock units issued at $0 that will vest in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or before the fourth anniversary of the grant, and subject to his continuous service to the company. The filing also discloses 25,000 shares held indirectly by a family trust. The Form 4 was submitted by one reporting person and signed by an attorney-in-fact on 10/02/2025.
Christian Waage, Executive Vice President, Tech Ops and Admin at Gossamer Bio, Inc. (GOSS), received a performance stock unit award of 125,000 shares on 10/01/2025. The award has a $0 purchase price and will vest in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or before the fourth anniversary of the grant, subject to continuous service. Following the grant, Mr. Waage is reported to beneficially own 710,934 shares directly, plus 45,892 shares held by a family trust and 22,222 held in a trust for his son. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Gossamer Bio, Inc. (GOSS) Chief Operating and Financial Officer Bryan Giraudo reported an award of 181,250 performance stock units on 10/01/2025. The award is a non‑cash grant that will vest in full upon the earlier of: approval of a new drug application for seralutinib or a change in control, provided vesting occurs on or before the fourth anniversary of the grant and the reporting person remains in continuous service. Following the reported grant, Mr. Giraudo beneficially owns 273,987 shares directly and 480,010 shares indirectly through a family trust, for combined reported beneficial ownership disclosed on the form.
Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc. (GOSS), reported receiving a performance stock unit award of 162,500 common stock units on 10/01/2025. The award carries a $0 purchase price and will vest in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, provided vesting occurs on or before the fourth anniversary of the grant date and subject to the reporting person’s continuous service. After the reported transaction, the filing shows 369,356 shares beneficially owned directly and 2,539 shares beneficially owned indirectly through a family trust. The filing was signed by an attorney-in-fact on 10/02/2025.
Hasnain Faheem, President & CEO and a director of Gossamer Bio, Inc. (GOSS), reported a non‑derivative acquisition dated 10/01/2025 of 437,500 performance stock units at a reported price of $0. After the award, the filing shows 557,793 shares beneficially owned directly and 5,408,073 shares beneficially owned indirectly through a family trust. The performance stock units will vest in full upon the earlier of the approval of a new drug application for seralutinib or a change in control, in either case on or before the fourth anniversary of the grant date, and are subject to the reporting person’s continuous service to the issuer. The Form 4 was signed on 10/02/2025 by an attorney‑in‑fact.
Caryn Peterson, Executive Vice President, Regulatory Affairs of Gossamer Bio, Inc. (GOSS), reported the acquisition of 125,000 performance stock units on 10/01/2025. The award is a performance stock unit grant that vests in full upon the earlier of (i) approval of a new drug application for seralutinib or (ii) a change in control, in either case on or before the fourth anniversary of the grant date, and is subject to the reporting person’s continuous service. After the transaction the reporting person beneficially owns 174,833 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.